# US 9,751,936 B2 · Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,751,936 B2
- Document ID: US9751936B2
- Status: Granted
- Kind: B2
- Application number: 14/768,182
- Filed: 2014-02-26
- Published: 2015-12-31
- Granted: 2017-09-05
- Earliest claimed: 2013-03-08
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Nicholas J. Papadopoulos
- Web page: https://patentgrep.com/patent/US9751936B2

## CPC

- C07K 16/20: from protozoa
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides antibodies that bind to serum resistance-associated (SRA) protein of Trypanosoma brucei rhodesiense, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to SRA. The antibodies of the invention are useful for inhibiting or neutralizing SRA activity, thus providing a means of treating human African trypanosomiasis (sleeping sickness), and symptoms associated with the disease. The antibodies of the invention may also be useful for diagnosis of sleeping sickness.

## Claims

### Claim 1

An isolated antibody or antigen-binding fragment thereof that binds specifically to SRA at pH7.4 and remains bound at pH4;
the antibody or antigen binding fragment thereof comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, and 274/282.

### Claim 2

An isolated antibody or antigen-binding fragment thereof that binds specifically to SRA at 25° C. and acidic pH with a dissociative half-life (t½) of less than about 4 minutes, wherein the antibody binds to SRA at 25° C. at neutral pH with a t½ of greater than about 20 minutes, as determined by surface plasmon resonance;
the antibody or antigen binding fragment thereof comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, and 274/282.

### Claim 3

An isolated antibody or antigen-binding fragment thereof that binds specifically to SRA at 25° C. and acidic pH with a dissociative half-life (t½) of less than about 100 minutes, wherein the antibody binds to SRA at 25° C. at neutral pH with a t½ of greater than about 150 minutes, as determined by surface plasmon resonance;
the antibody or antigen binding fragment thereof comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, and 274/282.

### Claim 4

An isolated antibody or antigen-binding fragment thereof that binds specifically to SRA at acidic pH and at neutral pH, wherein the dissociation rate constant (kd) for the antibody binding to SRA at 25° C. is less than about 1.7×10−2, as determined by surface plasmon resonance;
the antibody or antigen binding fragment thereof comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, and 274/282.

### Claim 5

An isolated antibody or antigen-binding fragment thereof that binds specifically to SRA, wherein the antibody or antigen-binding fragment thereof binds to an epitope on SRA (SEQ ID NO: 290) comprising an amino acid selected from the group consisting of S-174, I-175, V-176, K-177, K-178, P-179, K-180, G-181, A-182, P-183, D-184, K-185, T-186, A-187, A-188, D-189, E-190, L-191, V-192, T-193 and A-194;
wherein the antibody comprises:
three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained within any one of the heavy chain variable region (HCVR) sequences selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, and 274; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within any one of the light chain variable region (LCVR) sequences selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266 and 282.

### Claim 6

An isolated antibody or antigen-binding fragment thereof that competes for specific binding to SRA with an antibody or antigen-binding fragment comprising three CDRs of a HCVR, wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, and 274; and three CDRs of a LCVR, wherein the LCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, and 282.

### Claim 7 (depends on 6)

The isolated antibody or antigen-binding fragment thereof of claim 6, comprising:
(a) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, and 276;
(b) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, and 278;
(c) a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 232, 248, 264, and 280;
(d) a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, and 284;
(e) a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, and 286; and
(f) a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, 240, 256, 272, and 288.

### Claim 8 (depends on 7)

The isolated antibody or antigen-binding fragment of claim 7, wherein the antibody:
blocks SRA binding to apoL1, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 66/74, 98/106, 130/138, 146/154, 162/170, 210/218, 226/234, 242/250, 258/266, and 274/282; or
does not block SRA binding to apoL1, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 82/90, 114/122, 178/186, and 194/202.

### Claim 9

An isolated antibody or antigen-binding fragment thereof that binds to SRA and blocks SRA binding to apoL1 at pH ranging from about 7.4 to about 4.5, the antibody or antigen-binding fragment thereof comprising three CDRs of a HCVR, wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 66, 98, 130, 146, 162, 210, 226, 242, 258, and 274; and three CDRs of a LCVR, wherein the LCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 74, 106, 138, 154, 170, 218, 234, 250, 266, and 282.

### Claim 10

An isolated antibody or antigen-binding fragment thereof that binds to SRA and blocks SRA binding to apoL1 at pH4.5, the antibody or antigen-binding fragment thereof comprising three CDRs of a HCVR, wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 66, 98, 130, 146, 162, 210, 226, 242, 258, and 274; and three CDRs of a LCVR, wherein the LCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 74, 106, 138, 154, 170, 218, 234, 250, 266, and 282.

### Claim 11 (depends on 10)

A pharmaceutical composition comprising an isolated human antibody or antigen-binding fragment thereof that binds to SRA according to claim 10 and a pharmaceutically acceptable carrier or diluent
wherein the antibody or antigen-binding fragment thereof comprises the HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 66/74, 98/106, 130/138, 146/154, 162/170, 210/218, 226/234, 242/250, 258/266, and 274/282.

### Claim 12 (depends on 11)

A method for treating a patient suffering from sleeping sickness, or for treating at least one symptom or complication associated with sleeping sickness, or for treating a patient at risk for developing sleeping sickness, the method comprising administering to the patient a pharmaceutical composition comprising an effective amount of an antibody or an antigen-binding fragment thereof that binds to SRA according to claim 11, such that the sleeping sickness—associated condition or disease is either prevented, or lessened in severity and/or duration, or at least one symptom or complication associated with the condition or disease is prevented, or ameliorated, or that the frequency and/or duration of, or the severity of sleeping sickness is reduced.

### Claim 13

An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds serum resistance-associated (SRA) protein from Trypanosoma spp, wherein the antibody comprises:
three heavy chain complementarity determining region (CDRs) HCDR1, HCDR2 and HCDR3 comprising SEQ ID NOs: 68, 70 and 72; and
three light chain CDRs (LCDR1, LCDR2, and LCDR3 comprising SEQ ID NOs: 76, 78 and 80.

### Claim 14 (depends on 13)

The isolated monoclonal antibody of claim 13, which binds to an epitope on SRA SEQ ID NO. 290.

### Claim 15 (depends on 14)

The isolated monoclonal antibody of claim 14, wherein the epitope to which the antibody binds comprises an amino acid selected from the group consisting of S-174, I-175, V-176, K-177, K-178, P-179, K-180, G-181, A-182, P-183, D-184, K-185, T-186, A-187, A-188, D-189, E-190, L-191, V-192, T-193 and A-194.

### Claim 16

An isolated monoclonal antibody or antigen-binding fragment thereof that binds specifically to serum resistance-associated (SRA) protein from Trypanosoma spp, wherein the antibody comprises:
three heavy chain complementarity determining region (CDRs) HCDR1, HCDR2 and HCDR3 comprising SEQ ID NOs: 68, 70 and 72; and
three light chain CDRs (LCDR1, LCDR2, and LCDR3 comprising SEQ ID NOs: 76, 78 and 80,
wherein the antibody binds to an epitope on SEQ ID NO. 290 of SRA wherein the epitope to which the antibody binds comprises an amino acid selected from the group consisting of S-174, I-175, V-176, K-177, K-178, P-179, K-180, G-181, A-182, P-183, D-184, K-185, T-186, A-187, A-188, D-189, E-190, L-191, V-192, T-193 and A-194.

### Claim 17 (depends on 13)

The monoclonal antibody of claim 13, wherein the heavy chain variable region is comprised of SEQ ID NO:66.

### Claim 18 (depends on 13)

The monoclonal antibody of claim 13, wherein the light chain variable region comprises SEQ ID NO:74.

### Claim 19 (depends on 13)

The monoclonal antibody of claim 13, wherein the heavy chain variable region and light chain variable region are respectively defined by SEQ ID NO PAIR: 66/74.

### Claim 20 (depends on 16)

The monoclonal antibody of claim 16, wherein the heavy chain variable region is comprised of SEQ ID NO:66.

### Claim 21 (depends on 16)

The monoclonal antibody of claim 16, wherein the light chain variable region comprises SEQ ID NO:74.

### Claim 22 (depends on 16)

The monoclonal antibody of claim 16, wherein the heavy chain variable region and light chain variable region are respectively defined by SEQ ID NO PAIR: 66/74.